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Abstract. In the experiment, was made a simulation of endothelial dysfunction in male rats of 
Wistar-line byintraperitoneal administration of L-NAME at a dose of 25 mg/kg/day for 7 days. 
Deficiency of nitric oxide in result of the blockade of NO-synthase was accompanied by violation 
of endothelium-dependent and endothelium-undependentvasodilation assessed in 
pharmacological trials, which was reflected in the increase of the coefficient endotelialny 
dysfunction.In this case, for correction of endothelial dysfunction intraperitoneallyademetionine 
in the dose of 150 mg/kg and after an hour taurine at a dose of 260 mg/kg was injected the animal 
once a day for 7 days. 
The method provides effective impact of the combination of hepatoprotectorAdemetionine in the 
dose of 150 mg/kg/day and a sulfur-containing amino acid Taurine in the dose of 260 mg/kg/day 
on the functioning of the vascular endothelium, and has endotheliopathy effect on models L-
NAME-induced deficiency of nitric oxide, which includesthe endothelium-dependent 
vasodilation and the decrease of coefficient of endothelial dysfunction. 
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Intro: As already known, the endothelium 
maintains homeostasis by regulating the balance of 
opposing processes: vascular tone, responsible for 
vasodilation and vasoconstriction; anatomical 
structure of blood vessels, regulating the synthesis 
and the inhibition factors of cell proliferation; 
hemostasis, participating in the synthesis and 
inhibition of fibrinolysis factors and platelet 
aggregation; local inflammation by producing Pro - 
and anti-inflammatory cytokines [1, 2, 3, 4]. The 
endothelium lines all vessels, regardless of their 
organ localization, so endothelial dysfunction, the 
basis of which is reduced synthesis of endothelial cell 
nitric oxide (NO) is a predictor of diseases, not only 
arteries and veins, but components of the 
microvasculature [5, 6]. Endothelial dysfunction 
explains the pathogenesis of diseases such as 
hypertension, atherosclerosis, coronary artery 
disease, cardiomyopathy, pathogenesis of chronic 
heart failure, metabolic disorders: hyperlipidemia, 
hyperhomocysteinemia, hypoestrogenemia, diabetic 
vascular lesions, venous transformation [7, 8, 9, 10]. 
Therefore, the goal of our research was the search of 
drugs, their combinations are capable of correcting 
endothelial dysfunction, having endotheliopathy 
effect.From the literature it is known that taurine has 
antihypertensive, antioxidant [11] activities, 
contributes to endothelium-independent 
vasodilatation [12], the lack of endogenous taurine 
inhibits the processes of vasorelaxation[13]. 
Endothelial dysfunction is a prerequisite for the 
development of atherosclerosis. 
It is known that under the action of 
ademetionine normalization coefficient of endothelial 
dysfunction and that treatment with S-adenosyl-l-
methionine (SAM) prevents endothelial dysfunction 
in animals by induction of hemoxygenase-1 (HO-1) 
in endothelial cells of blood vessels and I believe that 
treatment (CAM) may represent a new therapeutic 
strategy for atherosclerosis [14, 15]. 
Main part: In connection with the foregoing, 
the purpose of this study was the investigationthe 
endotheliopathy properties of a combination of 
ademetionine in the dose of 150 mg/kg/day and 
taurine at a dose of 260 mg/kg/day as one of the 
possible effective combinations with dysfunction of 
endothelium, L-NAME-induced [16, 17, 18] 
deficiency of nitric oxide. 
Materials and methods research.Experiments 
were carried out on white rats-males of Wistar-line 
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weighing 170-220 g. (n=10 animals). L-NAME was 
injected intraperitoneally at a dose of 25 mg/kg/day. 
Ademetionine and taurine and their combination are 
entered daily intragastrically (by gavage) at doses of 
150 mg/kg/day and 260 mg/kg/day accordingly, at 
intervals of an hour, for 7 days.On the eighth day 
from the beginning of the experiment under 
combined anesthesia (chloralgidrate 150 mg/kg and 
zoletile 60 mg/kg) was injecteda catheter in the left 
carotid artery for registration of blood pressure (BP), 
vascular samples was carried out by introduction of a 
bolus into the left femoral vein of pharmacological 
agents.Hemodynamic parameters: systolic blood 
pressure (SBP), diastolic blood pressure (DBP) and 
heart rate (HR), measured continuously by a sensor 
TSD104A and hardware-software complex MP100, 
production Biopac System, Inc., USA.Functional 
tests: endothelium-dependent vasodilation the (EDV) 
– intravenous administration of acetylcholine (AH) at 
a dose of 40 mg/kg, endothelium-independent 
vasodilation (EIV) – intravenous injection 
ofnitroprusside sodium (NP) at a dose of 30 µg/kg. 
To assess the degree of endothelial dysfunction 
in experimental animals and its correction by 
researched drugs we have performed the calculation 
of the coefficient of endothelial dysfunction (CED) 
[16, 17, 18, 19]. 
With statistical data processing was calculated 
average value, standard deviation. The differences were 
considered significant at p<0.05. The normality of 
distribution was checked using the Shapiro-Wilk test. 
The results of research and their 
discussion:Arterial pressure in intact males were: 
systolic (SBP) – over 139.0±3.5 mm Hg, diastolic 
(DBP) – 105,0±2.9 mm Hg and HR - 420,0±9.0.The 
introduction of the blocker of NO-synthase, L-NAME, 
resulted in severe arterial hypertension (AH) (SBP – 
190,3±6,7, DBP – 145,0±3,9 mm Hg and HR – 
428,0±11,0) (Fig.1). During the simultaneous 
administration of L-NAME and ademetionine (150 
mg/kg) was observed decresing values of BP (SBP to 
160,2±12,6, DBP to 124.3±9,0, MBP to 136,1±10,2 
mm. Hg), monotherapy with taurine (260 mg/kg) – 
(SBP to 158,2±5,7, DBP 122,9±5,5, MBP 134,3±5.3 
mm. Hg) and with combination of ademetionine and 
taurine with L-NAME induced deficiency of nitric 
oxide indicators was reduced to the following nubers – 
SBP to 146,5±3,6, DBP to 126,4±3,0, MBP to 
133,6±3.2 mm. Hg.Bolus intravenous injection of AH 
within 3-5 secondsdecreased a blood pressure, reaching 
a peak in the intact animals for the SBP of 84.3±1,6 for 
DBP of 38.7±2.8 and for mean arterial pressure (MBP) 
55,8±1.7 mm. Hgwhile during the first 2-3 seconds 
developed sudden bradycardia up to 130-150 beats per 
minute. Restoring of the BP happened in average 
42,2±0,8 seconds after normalization of heart rate. EIV 
was also characterized by a decreasingof the SBP to 
87,0±2,8, DBP to 42.1±4,4, MBP to 55,7±3.5 mm Hg 
followed by full recovery within average 45,1±1,0 
sec.Blockade of NO-synthase with the help daily during 
the 7-day intraperitoneal injection of L-NAME at a dose 
of 25 mg/kg led to a smaller decline in BP after the 
introduction of AH (SBP to 110,6±5,2, DBP to 
82,8±6,6, MBP to 92.1±6,1 mm Hg) and NP (SBP to 
88,7±4,7, DBP to 50,8,8±4,2, MBP to 63,4±4,1 mm 
Hg) compared to the intact group. (table1). 
Tabel 1. 
Dynamics of blood pressure parameters and heart rate in the simulation of deficiency of nitric oxide  
and correction of endothelial dysfunction 
Animal group Functional tests DBP, mm Hg DBP, mm Hg HR, per minute 
Intact 
Source 139,0±3,5 105,0±2,9 420,0±9,0 
AH 84,3±1,6 38,7±2,8 - 
NP 87,0±2,8 42,1±4,4 - 
L-NAME (25 mg/kg) 
Source 190,3±6,7 145,0±3,9 
428,0±11,0 AH 110,6±5,2 82,8±6,6 
NP 88,7±4,7 50,8±4,2 
L-NAME (25 mg/kg) + 
ademetionine (150 
mg/kg) 
Source 160,2±12,6* 124,3±9,0 
320,5±15,6 AH 94,5±5,6 66,0±6,5 
NP 83,5±6,5 42,3±2,1 
L-NAME (25 mg/kg) + 
taurine (260 mg/kg) 
Source 158,2±5,7 122,9±5,5 
317,5±26,2 AH 113,8±1,8* 67,3±2,4 
NP 111,6±3,4* 46,2±1,8 
L-NAME (25 mg/kg)+ 
ademetionine (150 
mg/kg)+ taurine (260 
mg/kg) 
Source 146,5±3,6 126,4±3,0 
316,0±20,5 
AH 88,8±1,9 66,5±2,4 
NP 71,0±3,8 46,0±2,1 
p<0,05in comparison with the groupL-NAME 
*p<0,05in comparison with the group L-NAMEademetionine+ taurine 
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It was also noted potentiation of decrease in 
indicators of arterial pressure in response to the 
introduction of AH.The difference in EDV and EIV 
in the intact animals and animals with the 
introduction of the inhibitor of NO-synthase L-
NAME leads to the determination of the coefficient 
of endothelial dysfunction (CED) as the ratio of the 
area of the triangle above the trend of the reduction 
BP reaction in response to the introduction of AH.  
The CED is difference between intact group and 
the group treated with L-NAME in 5 times 
respectively of 1.2 and 5.2 in intact animals treated 
with L-NAME. (PokrovskayaT.G. monography). 
Thus, the obtained results allow us to conclude 
the activation of the correction of endothelial 
dysfunction with ademetionine in combined 
application with taurine (table 2). 
 
Table 2 
Dynamics of indicators that reflect the correction of endothelial dysfunction on the background of the introduction  
of L-NAME with ademetionine, taurine and their combination. 
Animalgroup Functionaltests 
The increase in 
the incidence 
of vascular 
response at 
Srad (mm Hg) 
Timevascularreactions Timevascularreactions 
CED (the area 
ratio of 
vascular 
responses AH 
to NP) 
L-NAME + 
адеметионин 
АХ 60,85,2 27,4±3,7 803,5±97,0 
4,6±0,5 
НП 918 76,8±5,1 3505,2±366,1 
L-NAME + 
таурин 
АХ 51,94,5 19,7±2,1 519,2±67,9 
4,3±0,7 
НП 674 56,1±5,1 1905,6±206,0 
L-NAME + 
адеметионин + 
таурин 
АХ 59,22,0 41,3±7,1 1139,2±136,2 
3,2±0,4* 
НП 784 83,3±2,4 3275,1±232,4 
*p<0,05 in comparison with the group L-NAMEademetionine+ taurine 
 
Thus, the results demonstrate that investigational 
drugs have not only antihypertensive effect but also 
contribute to the reduction of the coefficient of 
endothelial dysfunction in comparison with group L-
NAME (Fig.1). 
 
  
Figure 1. The values of the coefficient of endothelial dysfunction in correction with ademetionine (150 mg/kg/day), taurine 
(260 mg/kg/day) and their combination in comparison with the intact group and the group in modeling L-NAME (25 mg/kg 
intraperitoneally once daily for 7 days) induced NO deficit,  *- p<0.05 compared with group L-NAME. 
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Conclusion: On models L-NAME-induced deficit 
of nitrogen oxide are realized antihypertensive, 
antioxidant andendothelioprotectiveproperties of taurine 
and ademetionine, as according to the literature, 
inhibition of nitric oxide production in the application 
of L-NAME was accompanied by a significant increase 
in the spontaneous production of superoxide anion 
radical, hypertension and increase of coefficient of 
endothelial dysfunction [10, 20]. Hyperproduction of 
superoxide radical and its derivatives – oxygen radicals 
– is a mechanism for development of oxidative stress 
(OS), in which the suppression of the antioxidant 
defense system and increased formation of oxidation 
products, which arethe factors for the formation of 
endothelial dysfunction [21, 22, 23].In the study it was 
found that the combined using of ademetionine in the 
dose 150mg/kg/day and taurine at a dose of 260 
mg/kg/day to provides more endothelioprotective effect 
on models L-NAME-induced deficit of nitrogen oxide 
in comparison with monotherapy, which was reflected 
in the decrease of coefficient of endothelial dysfunction 
(CED) [24] and the BP values to a level close to the 
level of intact animals.Therefore, monotherapy 
endothelial dysfunction with ademetionine and taurine 
is regarded as insufficient, and leads to further search 
for more effective ways of pharmacotherapy, one of 
which is the combined application of taurine and 
ademetionine. From our point of view, the combination 
of ademetionine and taurineis warranted to examine 
itsendothelio - and cardioprotective effect. 
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